Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H11ClN6O2S2 |
Molecular Weight | 370.838 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=CC(C2=NN=NN2)=C(NCC3=CC=CS3)C=C1Cl
InChI
InChIKey=HMEDEBAJARCKCT-UHFFFAOYSA-N
InChI=1S/C12H11ClN6O2S2/c13-9-5-10(15-6-7-2-1-3-22-7)8(12-16-18-19-17-12)4-11(9)23(14,20)21/h1-5,15H,6H2,(H2,14,20,21)(H,16,17,18,19)
Molecular Formula | C12H11ClN6O2S2 |
Molecular Weight | 370.838 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/4011012Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/14520682
Sources: http://www.ncbi.nlm.nih.gov/pubmed/4011012
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/14520682
Azosemide is a monosulfamyl belonging to the class of loop diuretics, used to treat hypertension, edema, and ascites. Azosemide inhibits sodium and chloride reabsorption throughout the thick ascending limb of the loop of Henle. The exact mechanism of action is not fully understood, but it mainly acts on both the medullary and cortical segments of the thick ascending limb of the loop of Henle. Delayed tolerance was demonstrated in humans by homeostatic mechanisms (principally an increase in aldosterone secretion and perhaps also an increase in the reabsorption of solute in the proximal tubule). After oral administration to healthy humans in the fasting state, the plasma concentration of azosemide reached its peak at 3–4 h with an absorption lag time of approximately 1 h and a terminal half-life of 2–3 h. The estimated extent of absolute oral bioavailability in humans was approximately 20.4%. After oral administration of the same dose of azosemide and furosemide, the diuretic effect was similar between the two drugs, but after intravenous administration, the effect of azosemide was 5.5–8 times greater than that in furosemide. This could be due to the considerable first-pass effect of azosemide. Azosemide is actively secreted in the renal proximal tubule possibly via nonspecific organic acid secretory pathway in humans. Thus, the amount of azosemide that reaches its site of action could be significantly modified by changes in the capacity of this transport system. This capacity, in turn, could be predictably changed in disease states, resulting in decreased delivery of the diuretic to the transport site, as well as in the presence of other organic acids such as nonsteroidal anti-inflammatory drugs which could compete for active transport of azosemide.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | Unknown Approved UseUnknown |
|||
Sources: http://www.ncbi.nlm.nih.gov/pubmed/4011012 |
Secondary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/14520682
60-90 mg/day
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/2080229
Direct effect of azosemide on the mouse thick ascending limb of Henle's loop was examined by the isolated tubules perfusion technique, and the effect was compared with that of furosemide. Azosemide added to the tubular lumen reversibly suppressed the lumen positive potential (PDt) and decreased the net chloride reabsorption. At a concentration of 10(-5) mol/l azosemide suppressed PDt by 91.4%.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:17:50 UTC 2023
by
admin
on
Fri Dec 15 15:17:50 UTC 2023
|
Record UNII |
MR40VT1L8Z
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C49184
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3954
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
18651
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1097235
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
248-549-7
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
MR40VT1L8Z
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
DTXSID7046910
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
2273
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
31248
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
SUB05663MIG
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
27589-33-9
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
m2185
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | Merck Index | ||
|
C77515
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
AZOSEMIDE
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
100000086087
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
DB08961
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
C018222
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY | |||
|
278
Created by
admin on Fri Dec 15 15:17:50 UTC 2023 , Edited by admin on Fri Dec 15 15:17:50 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|